Soma (Carisoprodol)
Brand Names: Soma
Methodology & AI Transparency ⓘ
Soma (Carisoprodol) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Soma (Carisoprodol) represents a prescription brand-name muscle relaxant entry registered by Viatris Specialty LLC with package codes 0037-2001, 0037-2250.
- 2 Real-world patient consensus: Branded muscle relaxant presentation of Carisoprodol (Viatris Specialty LLC); generic reference: /meds/carisoprodol.
- 3 Typical cash cost range: Dispensing cost comparison spans $640.00 mail/discount cash up to $1696.00 uninsured retail (federal NADAC $11.2975).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Soma (Carisoprodol) include headache (8.9%), dizziness (8.2%), somnolence (5.3%).
Ask our AI Specialists anything about Soma (Carisoprodol)
Soma (Carisoprodol) Mechanism, CYP450 Pathways & DailyMed Monograph
Soma (Carisoprodol) represents a prescription brand-name muscle relaxant entry registered by Viatris Specialty LLC with package codes 0037-2001, 0037-2250. Reviewed against 2026-03-17 FDA SPL standards (350 mg/1 Tablet; 250 mg/1 Tablet), clinical deployment addresses Carisoprodol tablets are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions.
Soma achieves therapeutic action via Carisoprodol, engaging muscle relaxant physiological pathways with class-characteristic hepatorenal disposition. Manufactured in 350 mg/1 Tablet; 250 mg/1 Tablet (registered by Viatris Specialty LLC, NDC 0037-2001, 0037-2250), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Soma ($1696.00 retail) with generic Carisoprodol ($640.00 low cash).
Systemic exposure to Soma (Carisoprodol) reflects Oral fraction absorbed ranges from 71% to 83% (Soma (Carisoprodol) 350) absorption kinetics and dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of soma (carisoprodol), sustaining receptor engagement across a Mean elimination half-life of 7 to 12 hours across adult Soma (Carisoprodol) dosing half-life window (oral tmax achieved within 2 to 5 hours following soma (carisoprodol) ingestion response profile).
Dosing protocols (350 mg/1 Tablet or 250 mg/1 Tablet) balance efficacy (93.00% patient satisfaction across 22 logs) against nausea (9.3% of reports), headache (8.9% of reports), dizziness (8.2% of reports), with strict avoidance in contraindicated in patients with prior serious allergic response to soma (carisoprodol) (ndc 0037-2001); severe baseline organ impairment where carisoprodol accumulation exceeds safe therapeutic margins.
Concurrent opioid, benzodiazepine, or alcohol intake amplifies drowsiness and respiratory suppression with Soma (Carisoprodol).
Reconcile eGFR-adjusted medications before escalating Soma (Carisoprodol) in polypharmacy regimens.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Soma (Carisoprodol) (NDC 0037-2001)
- Severe baseline organ impairment where Carisoprodol accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (22 Reports)
Soma (Carisoprodol) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Soma (Carisoprodol))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Somatic complaints in anxious: What a 488-Participant Study Found Physical symptoms decreased over the course of treatment, and were unrelated to treatment condition. Child psychiatry and human development • 2014-08-15 • Randomized Controlled Trial | N = 488 | 93/100 | PMID 24129543 ↗ |
| New Insights on Benefits and safety of etifoxine versus alprazolam in generalized anxiety with: What a 260-Participant Study Found Treatment-emergent AEs were mild and observed in 10% and 7.7% of patients in the Etifoxine and Alprazolam groups, respectively. Journal of anxiety disorders • 2026-04-15 • Phase III Randomized Trial | N = 260 | 93/100 | PMID 41763071 ↗ |
| Can This Approach Help? Inside the Latest Research on Reduced breakthrough symptom exacerbations in patients with biochemically In patients with acromegaly biochemically controlled with injected SRLs, switching to once-daily oral paltusotine was associated with stable biochemical control, stable symptom severity, and a significantly reduced frequency... Pituitary • 2026-07-23 • Phase III Randomized Trial | N = 22 | 88/100 | PMID 42493688 ↗ |
| Can This Approach Help? Inside the Latest Research on A Phase 3 Active-Controlled Trial of Liposomal Bupivacaine via Adductor Canal Liposomal bupivacaine administered via adductor canal block for total knee arthroplasty was associated with concurrent reductions in pain and opioid consumption compared with bupivacaine during the first 96 hours after surgery. The Journal of arthroplasty • 2025-10-15 • Phase III Randomized Trial | N = 167 | 88/100 | PMID 40701284 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy in Japanese adults with growth hormone deficiency receiving weekly In Japanese treatment-naïve individuals with AGHD, once-weekly somapacitan demonstrated similar real-world benefits and safety to daily GH after 34 weeks of treatment. Frontiers in endocrinology • 2025-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39991735 ↗ |
Soma (Carisoprodol) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $11.2975/unit (~$338.92/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1696.00 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $640.00 / mo | View logs ↓ |
Soma (Carisoprodol) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Soma (Carisoprodol) RxNorm Concept ID | RXN-B00372001 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $11.2975 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1696.00 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $640.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 93.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Soma (Carisoprodol) Patient Community, Cohort Filters & Dosage Logs
Deterministic Soma (Carisoprodol) reference combining NIH RxNorm (RXN-B00372001), Medicaid NADAC ($11.2975/unit), and anonymous cohort outcomes (93% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Soma (Carisoprodol) community threads and patient logs by age, biological sex, dosage, and treatment duration.